Baudax Bio (NASDAQ: BXRX) is one of 27 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it compare to its competitors? We will compare Baudax Bio to related companies based on the strength of its risk, profitability, valuation, analyst recommendations, dividends, institutional ownership and earnings.
Volatility & Risk
Baudax Bio has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Baudax Bio’s competitors have a beta of 7.07, indicating that their average share price is 607% more volatile than the S&P 500.
This table compares Baudax Bio and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Baudax Bio||$490,000.00||-$76.10 million||-0.35|
|Baudax Bio Competitors||$1.94 billion||$96.17 million||42.17|
Baudax Bio’s competitors have higher revenue and earnings than Baudax Bio. Baudax Bio is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Baudax Bio and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Baudax Bio Competitors||-39.15%||16.05%||-9.95%|
This is a summary of current recommendations for Baudax Bio and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Baudax Bio Competitors||92||389||536||15||2.46|
As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 9.69%. Given Baudax Bio’s competitors higher possible upside, analysts clearly believe Baudax Bio has less favorable growth aspects than its competitors.
Insider and Institutional Ownership
10.4% of Baudax Bio shares are held by institutional investors. Comparatively, 43.2% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 2.6% of Baudax Bio shares are held by company insiders. Comparatively, 26.4% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Baudax Bio competitors beat Baudax Bio on 8 of the 10 factors compared.
About Baudax Bio
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Receive News & Ratings for Baudax Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baudax Bio and related companies with MarketBeat.com's FREE daily email newsletter.